NCT05481333View on ClinicalTrials.gov

A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 24, 2022

Primary Completion Date

August 29, 2023

Study Completion Date

August 29, 2023

Conditions
Healthy
Interventions
DRUG

REGN7999

Ascending IV or SC dose administered per protocol

DRUG

Placebo

Ascending IV or SC dose administered per protocol

Trial Locations (1)

9000

Drug Research Unit Gent, Ghent

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY